Search Results 351-360 of 17470 for Vitiligo

1. A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma - Mayo Clinic

   ... vitiligo, or asthma not requiring systemic steroids. Known HIV or chronic Hepatitis B or C infection. Known hypersensitivity to any temozolomide component ...

2. SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab - Mayo Clinic

   Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not ...

3. A Phase Ⅲ Study Of Rilvegostomig In Combination With Fluoropyrimidine And Trastuzumab Deruxtecan As The First-line Treatment For HER2-positive Gastric Cancer - Mayo Clinic

   Vitiligo. Endocrine disorders, that are controlled with replacement hormone therapy. Residual Grade 1 or Grade 2 endocrinopathies from prior immune CPIs may ...

4. Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   Eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only provided all of following are true: Rash covers < 10% of body ...

5. Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer - Mayo Clinic

   Patients with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Patients that require intermittent use of bronchodilators or ...

6. A Study to Compare Radiation Therapy + Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer - Mayo Clinic

   Participation eligibility · Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with ...

7. A Study to Evaluate the Effectiveness and Safety of rAd-IFN Administered With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma - Mayo Clinic

   NOTE: patients with vitiligo, residual hypothyroidism due to auto immune disease only requiring hormone replacement, psoriasis not requiring systemic ...

8. Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma - Mayo Clinic

   Patients with isolated vitiligo remain eligible. Any patient with an allo-transplant of any kind would be excluded as well, including xenograft heart valve ...

9. Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer - Mayo Clinic

   Patients with eczema, psoriasis, lichen simplex chronicus of vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would ...

10. A Study to Assess the Effectiveness and Safety of Durvalumab Alone or Combined with Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment - Mayo Clinic

    Participation eligibility · Patients with vitiligo or alopecia; · Patients with hypothyroidism (e.g., following Hashimoto syndrome), stable on hormone replacement ...